Astrazeneca (AZN) Gross Profit (2016 - 2026)

Generated on {Timestamp} © BusinessQuant.com

Generated on {Timestamp} Powered by

Astrazeneca has reported Gross Profit over the past 16 years, most recently at $12.6 billion for Q1 2026.

• For Q1 2026, Gross Profit rose 11.13% year-over-year to $12.6 billion; the TTM value through Mar 2026 reached $49.4 billion, up 10.32%, while the annual FY2025 figure was $48.1 billion, 9.67% up from the prior year.
• Gross Profit for Q1 2026 was $12.6 billion at Astrazeneca, up from $12.4 billion in the prior quarter.
• Over five years, Gross Profit peaked at $12.6 billion in Q1 2026 and troughed at $7.8 billion in Q2 2022.
• A 5-year average of $10.2 billion and a median of $10.5 billion in 2024 define the central range for Gross Profit.
• Biggest five-year swings in Gross Profit: skyrocketed 82.77% in 2022 and later grew 1.8% in 2025.
• Year by year, Gross Profit stood at $8.3 billion in 2022, then rose by 16.96% to $9.7 billion in 2023, then grew by 25.22% to $12.2 billion in 2024, then increased by 1.8% to $12.4 billion in 2025, then increased by 1.82% to $12.6 billion in 2026.
• Business Quant data shows Gross Profit for AZN at $12.6 billion in Q1 2026, $12.4 billion in Q4 2025, and $12.4 billion in Q3 2025.

Peer Comparison